

# Ronald F Van Vollenhoven

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/688412/publications.pdf>

Version: 2024-02-01

135  
papers

22,669  
citations

53660

45  
h-index

13727

129  
g-index

169  
all docs

169  
docs citations

169  
times ranked

17278  
citing authors

#	ARTICLE	IF	CITATIONS
1	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.5	3,366
3	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.5	1,860
4	A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011, 63, 3918-3930.	6.7	1,277
5	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 736-745.	0.5	1,265
6	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.5	1,114
7	Joint European League Against Rheumatism and European Renal Association "European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1771-1782.	0.5	868
8	Systemic lupus erythematosus. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16039.	18.1	816
9	Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2012, 367, 508-519.	13.9	810
10	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.5	558
11	2019 Update of the Joint European League Against Rheumatism and European Renal Association "European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 713-723.	0.5	463
12	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1706-1713.	0.5	391
13	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016, 55, 252-262.	0.9	370
14	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 16-22.	0.5	275
15	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.5	268
16	Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials. <i>Journal of Rheumatology</i> , 2010, 37, 558-567.	1.0	265
17	Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. <i>Lancet</i> , The, 2018, 392, 1330-1339.	6.3	244
18	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. <i>Lancet</i> , The, 2014, 383, 321-332.	6.3	232

#	ARTICLE	IF	CITATIONS
19	Sex differences in rheumatoid arthritis: more than meets the eye.... BMC Medicine, 2009, 7, 12.	2.3	230
20	Treatment of rheumatoid arthritis: state of the art 2009. Nature Reviews Rheumatology, 2009, 5, 531-541.	3.5	216
21	Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis and Rheumatism, 2007, 56, 1263-1272.	6.7	213
22	Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. Journal of Rheumatology, 2015, 42, 1761-1766.	1.0	194
23	Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Annals of the Rheumatic Diseases, 2011, 70, 469-475.	0.5	159
24	Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Annals of the Rheumatic Diseases, 2016, 75, 1081-1091.	0.5	152
25	Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatology, The, 2021, 3, e778-e788.	2.2	130
26	Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Annals of the Rheumatic Diseases, 2021, 80, 304-311.	0.5	129
27	Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-naïve Patients With Moderately-to-severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-blind, Active Comparator-controlled Trial. Arthritis and Rheumatology, 2020, 72, 1607-1620.	2.9	126
28	Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 52-58.	0.5	111
29	A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis. Arthritis and Rheumatology, 2016, 68, 2174-2183.	2.9	105
30	2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine, 2021, 8, e000538.	1.1	97
31	Treat-to-target in rheumatoid arthritis "are we there yet?". Nature Reviews Rheumatology, 2019, 15, 180-186.	3.5	86
32	Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Annals of the Rheumatic Diseases, 2015, 74, 1102-1109.	0.5	83
33	Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open, 2019, 9, e025687.	0.8	81
34	Antinuclear Antibody-negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	1.5	70
35	Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis. Arthritis and Rheumatology, 2017, 69, 1751-1761.	2.9	65
36	Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. Rheumatology, 2016, 55, 1031-1041.	0.9	62

#	ARTICLE	IF	CITATIONS
37	Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort. <i>Lupus Science and Medicine</i> , 2017, 4, e000192.	1.1	61
38	Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: Work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. <i>Arthritis Care and Research</i> , 2010, 62, 226-234.	1.5	56
39	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1478-1487.	1.5	55
40	Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. <i>Nature Reviews Rheumatology</i> , 2022, 18, 146-157.	3.5	55
41	Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial. <i>RMD Open</i> , 2017, 3, e000458.	1.8	54
42	Clinical responses to tumor necrosis factor ? antagonists do not show a bimodal distribution: Data from the Stockholm Tumor Necrosis Factor ? Followup Registry. <i>Arthritis and Rheumatism</i> , 2003, 48, 1500-1503.	6.7	51
43	Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response. <i>Rheumatology</i> , 2013, 52, 847-855.	0.9	51
44	Off-label use of rituximab for systemic lupus erythematosus in Europe. <i>Lupus Science and Medicine</i> , 2016, 3, e000163.	1.1	51
45	Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus <i>vs</i> matched controls. <i>Rheumatology</i> , 2021, 60, 207-216.	0.9	51
46	Dehydroepiandrosterone for the treatment of systemic lupus erythematosus. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 23-31.	0.9	48
47	Note of Republication: A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 1074-1082.	2.3	48
48	Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab. <i>RMD Open</i> , 2016, 2, e000213.	1.8	47
49	Advances in the treatment of rheumatoid arthritis. <i>F1000prime Reports</i> , 2014, 6, 31.	5.9	44
50	Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1094-1101.	0.5	43
51	Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious. <i>Arthritis Research</i> , 2003, 5, R347.	2.0	42
52	Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. <i>Rheumatology</i> , 2017, 56, kew370.	0.9	42
53	Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. <i>Pharmacogenomics Journal</i> , 2018, 18, 528-538.	0.9	42
54	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 370-378.	0.5	42

#	ARTICLE	IF	CITATIONS
55	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 356-362.	0.5	40
56	Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population. <i>Lancet Rheumatology</i> , The, 2020, 2, e583-e585.	2.2	40
57	Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase <sc>II</sc> Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020, 72, 761-768.	2.9	38
58	Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. <i>Arthritis Research and Therapy</i> , 2016, 18, 50.	1.6	37
59	The relationship between remission and health-related quality of life in a cohort of SLE patients. <i>Rheumatology</i> , 2019, 58, 628-635.	0.9	36
60	Unresolved issues in biologic therapy for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2011, 7, 205-215.	3.5	34
61	Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. <i>Lancet Rheumatology</i> , The, 2022, 4, e417-e429.	2.2	33
62	Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1567-1570.	0.5	31
63	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. <i>Lupus Science and Medicine</i> , 2021, 8, e000590.	1.1	31
64	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring <sc>SLE</sc>: Assessment by Drug Levels and Self-administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 374-382.	2.3	30
65	A Multi-biomarker Disease Activity Score and the Choice of Second-line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure. <i>Arthritis and Rheumatology</i> , 2017, 69, 953-963.	2.9	27
66	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020, 106, 102340.	3.0	27
67	Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial. <i>BMC Medicine</i> , 2015, 13, 247.	2.3	26
68	Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000371.	1.8	26
69	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020, 72, 658-666.	2.9	26
70	Progress in RA genetics, pathology and therapy. <i>Nature Reviews Rheumatology</i> , 2013, 9, 70-72.	3.5	25
71	Efficacy of tofacitinib monotherapy in methotrexate-naïve patients with early or established rheumatoid arthritis. <i>RMD Open</i> , 2016, 2, e000262.	1.8	24
72	Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review. <i>Lupus Science and Medicine</i> , 2021, 8, e000542.	1.1	24

#	ARTICLE	IF	CITATIONS
73	Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1556-1563.	0.5	24
74	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020, 72, 1800-1808.	1.5	23
75	Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. <i>RMD Open</i> , 2020, 6, e001370.	1.8	23
76	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1231-1235.	1.5	22
77	Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial. <i>RMD Open</i> , 2016, 2, e000197.	1.8	21
78	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2018, 70, 1294-1302.	1.5	21
79	Remission in SLE: closing in on the target. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2103-2106.	0.5	19
80	Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 157-168.	1.4	19
81	Detection of clinically manifest and silent synovitis in the hands and wrists by fluorescence optical imaging. <i>RMD Open</i> , 2015, 1, e000106-e000106.	1.8	18
82	Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. <i>Lupus Science and Medicine</i> , 2022, 9, e000634.	1.1	18
83	Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration. <i>Journal of Rheumatology</i> , 2017, 44, 162-169.	1.0	17
84	Serum Biomarkers for Prediction of Response to Methotrexate Monotherapy in Early Rheumatoid Arthritis: Results from the SWEFOT Trial. <i>Journal of Rheumatology</i> , 2019, 46, 555-563.	1.0	17
85	Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. <i>Lancet Rheumatology</i> , The, 2022, 4, e441-e449.	2.2	17
86	B cell lymphoproliferative disorders and VH4-34 gene encoded antibodies. <i>Human Antibodies</i> , 2004, 13, 63-68.	0.6	16
87	Are dietary vitamin D, omega-3 fatty acids and folate associated with treatment results in patients with early rheumatoid arthritis? Data from a Swedish population-based prospective study. <i>BMJ Open</i> , 2017, 7, e016154.	0.8	16
88	Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials. <i>Lancet Rheumatology</i> , The, 2019, 1, e163-e173.	2.2	16
89	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2019, 46, 492-500.	1.0	15
90	Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 4752-4762.	0.9	15

#	ARTICLE	IF	CITATIONS
91	Toward Individualized Prediction of Response to Methotrexate in Early Rheumatoid Arthritis: A <scp>Pharmacogenomicsâ€Driven</scp> Machine Learning Approach. Arthritis Care and Research, 2022, 74, 879-888.	1.5	15
92	Choosing Wisely in Daily Practice: An Intervention Study on Antinuclear Antibody Testing by Rheumatologists. Arthritis Care and Research, 2016, 68, 562-569.	1.5	14
93	Blood PD-1+TFh and CTLA-4+CD4+ T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis. Rheumatology, 2022, 61, 1233-1242.	0.9	14
94	Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study. Journal of Rheumatology, 2022, 49, 380-387.	1.0	14
95	Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials. RMD Open, 2016, 2, e000323.	1.8	13
96	Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort. Lupus Science and Medicine, 2018, 5, e000287.	1.1	13
97	An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases. Rheumatology, 2020, 59, 1842-1852.	0.9	13
98	What Does it Mean to be a British Isles Lupus Assessment Groupâ€Based Composite Lupus Assessment Responder? Post Hoc Analysis of 2 Phase 3 Trials. Arthritis and Rheumatology, 2021, 73, 2059-2068.	2.9	12
99	COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases. Lancet Rheumatology, The, 2022, 4, e310-e313.	2.2	12
100	Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study. Lupus Science and Medicine, 2018, 5, e000288.	1.1	11
101	Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study. RMD Open, 2022, 8, e002035.	1.8	11
102	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€FI). Arthritis Care and Research, 2020, , .	1.5	9
103	New and future agents in the treatment of rheumatoid arthritis. Discovery Medicine, 2010, 9, 319-27.	0.5	9
104	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.5	9
105	Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2022, 74, 1822-1828.	1.5	9
106	Fully automated joint space width measurement and digital X-ray radiogrammetry in early RA. RMD Open, 2017, 3, e000369.	1.8	8
107	Triple therapy or etanercept after methotrexate failure in RA?. Nature Reviews Rheumatology, 2013, 9, 510-512.	3.5	7
108	Brief Report: Enhancement of Patient Recruitment in Rheumatoid Arthritis Clinical Trials Using a Multiâ€Biomarker Disease Activity Score as an Inclusion Criterion. Arthritis and Rheumatology, 2015, 67, 2855-2860.	2.9	7



#	ARTICLE	IF	CITATIONS
109	New therapeutic approaches in rheumatoid arthritis. <i>Presse Medicale</i> , 2016, 45, e179-e192.	0.8	7
110	Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence. <i>Lupus Science and Medicine</i> , 2021, 8, e000478.	1.1	7
111	Response to: "MBDA: what is it good for?" by Yazici et al. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e73-e73.	0.5	6
112	Does disease activity at start of biologic therapy influence work-loss in RA patients?. <i>Rheumatology</i> , 2016, 55, 729-734.	0.9	6
113	Long-Term Dietary Changes after Diagnosis of Rheumatoid Arthritis in Swedish Women: Data from a Population-Based Cohort. <i>International Journal of Rheumatology</i> , 2018, 2018, 1-7.	0.9	6
114	Joint Mobilization of the Hands of Patients With Rheumatoid Arthritis: Results From an Assessor-Blinded, Randomized Crossover Trial. <i>Journal of Manipulative and Physiological Therapeutics</i> , 2019, 42, 34-46.	0.4	6
115	Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study. <i>Modern Rheumatology</i> , 2021, 31, 534-542.	0.9	6
116	The association between diet and glucocorticoid treatment in patients with SLE. <i>Lupus Science and Medicine</i> , 2016, 3, e000135.	1.1	5
117	Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1065-1071.	0.4	5
118	Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry" by Sparks et al. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrheumdis-2021-221146.	0.5	4
119	Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	4
120	94. Tocilizumab in Patients with Rheumatoid Arthritis and Rates of Malignancy: Results from Long-Term Extension Clinical Trials. <i>Rheumatology</i> , 2014, 53, i91-i92.	0.9	3
121	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021, 30, 096120332110142.	0.8	3
122	Oral Abstracts 7: RA Clinical * O37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach. <i>Rheumatology</i> , 2013, 52, i44-i55.	0.9	2
123	Does disease activity at the start of biologic therapy influence health care costs in patients with RA?. <i>Rheumatology</i> , 2015, 54, 1472-1477.	0.9	2
124	Methotrexate for Prevention of Cardiovascular Events. <i>New England Journal of Medicine</i> , 2019, 380, 2276-2277.	13.9	2
125	Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine. <i>RMD Open</i> , 2021, 7, e001560.	1.8	2
126	Impact of Tofacitinib on Components of the ACR Response Criteria: Posthoc Analysis of Phase III and Phase IIIb/IV Trials. <i>Journal of Rheumatology</i> , 2022, , jrheum.210707.	1.0	2



#	ARTICLE	IF	CITATIONS
127	An ultrasound negative for subclinical synovitis in arthralgia patients: is it helpful in identifying those not developing arthritis?. <i>Rheumatology</i> , 2022, , .	0.9	2
128	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , 2017, 19, 287.	1.6	1
129	Infliximab in the treatment of rheumatoid arthritis. <i>Aging Health</i> , 2006, 2, 19-33.	0.3	1
130	CS-07â€¦Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
131	FRI0630â€¦DIAGNOSTIC UTILITY OF FLUORESCENCE OPTICAL IMAGING IN INDIVIDUALS WITH SUSPECTED ARTHRITIS â€œ A PROBABILISTIC APPROACH. , 2019, , .		0
132	THU0090â€¦MORTALITY OVER UP TO 14 YEARS FOLLOW-UP IN MTX-REFRACTORY PATIENTS RANDOMIZED TO A STRATEGY STARTING WITH ADDITION OF INFLIXIMAB OR ADDITION OF SULFASALAZINE AND HYDROXYCHLOROQUINE. , 2019, , .		0
133	Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquine. <i>Rheumatology</i> , 2021, 60, 2217-2222.	0.9	0
134	Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
135	Levelling the playing field of RMD research across Europe to address patientsâ€™ needs: the emerging EULAR Research Centre. <i>RMD Open</i> , 2022, 8, e002456.	1.8	0